Is ritexitinib tosylate the same as ritexinib?

Ritlecitinib Tosylate Capsules (Ritlecitinib) and Ritlecitinib Tosylate Capsules are actually different names for the same drug. Among them, ritexitinib tosylate is the generic name of the drug, while Lefenox is its trade name sold in China.

This drug is developed and produced by Pfizer and is mainly used to treat adolescents and adults aged 12 and above with severe alopecia areata. As an oral specific Janus kinase 3 (JAK3)/hepatocellular carcinoma (TEC) inhibitor, ritexitinib tosylate is highly selective for tyrosine kinases expressed in the JAK3 and TEC kinase families. It blocks signaling molecules and immune cell activity that cause alopecia areata, thereby inhibiting the immune system's stimulating effect on hair follicle cells, slowing or stopping hair loss, and promoting hair regeneration.

On the market, Rofenac is the trade name of the drug, while ritexitinib tosylate is its chemical name. The naming of drugs often distinguishes their chemical ingredients and commercial brands to facilitate identification by doctors and patients. In clinical applications, medical staff usually use trade names for prescription and promotion, while in drug development and scientific research, chemical names are more common.

The development process of ritixitinib has gone through multiple stages, including preliminary pharmacodynamic studies, clinical trials and subsequent marketing applications. Clinically, ritexitinib has shown significant efficacy, bringing new treatment hope to many patients with alopecia areata. However, patients should also be aware of drug side effects and interactions when using them. Common side effects include headache, diarrhea, acne, rash, etc., and allergic reactions may occur in severe cases. In addition, certain drugs may interact with ritexitinib tosylate, affecting its efficacy or increasing the risk of adverse reactions.